Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Leases: 2020-2024

Historic Current Leases for Anika Therapeutics (ANIK) over the last 5 years, with Dec 2024 value amounting to $1.9 million.

  • Anika Therapeutics' Current Leases fell 24.74% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 24.74%. This contributed to the annual value of $1.9 million for FY2024, which is 4.98% up from last year.
  • As of FY2024, Anika Therapeutics' Current Leases stood at $1.9 million, which was up 4.98% from $1.8 million recorded in FY2023.
  • Anika Therapeutics' 5-year Current Leases high stood at $2.1 million for FY2022, and its period low was $1.4 million during FY2020.
  • In the last 3 years, Anika Therapeutics' Current Leases had a median value of $1.9 million in 2024 and averaged $1.9 million.
  • Per our database at Business Quant, Anika Therapeutics' Current Leases skyrocketed by 35.85% in 2022 and then declined by 11.87% in 2023.
  • Anika Therapeutics' Current Leases (Yearly) stood at $1.4 million in 2020, then increased by 6.19% to $1.5 million in 2021, then spiked by 35.85% to $2.1 million in 2022, then declined by 11.87% to $1.8 million in 2023, then increased by 4.98% to $1.9 million in 2024.